Clinical trials: Osteoporosis, Postmenopausal
Endometrial Hyperplasia, Osteoporosis
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.
- Trial name
- NCT00242710
- Testing
- Bazedoxifene/Conjugated Estrogen, CE 0.45 mg/MPA 1.5mg
- Where
- 9 sites in United States
- Volunteers
- 1,083 people
- Sponsor
- Pfizer
Post Menopausal Osteoporosis
A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)
This study will determine the rapidity of suppression of the bone resorption marker sCTX in post-menopausal women with osteoporosis.Other bone turnover markers will also be evaluated.
- Trial name
- NCT00303485
- Testing
- Vitamin D and calcium supplementation, ibandronate [Bonviva/Boniva]
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Osteoporosis
Role of T-cells in Post-Menopausal Osteoporosis
This is an observational study of women undergoing surgical menopause to determine whether T-cells play an important role in the etiology of post-menopausal osteoporosis.
- Trial name
- NCT00787904
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Atlanta VA Medical Center
Osteoporosis, Postmenopausal
Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND
This is a randomized, double-blind, parallel design, repeat dose, 2 arm, multicenter study comparing the efficacy, safety, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of AVT03 and US-Prolia in…
- Trial name
- ALVOBOND (NCT05395091)
- Testing
- AVT03, Denosumab
- Where
- 34 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 532 people
- Sponsor
- Alvotech Swiss AG
Osteoporosis, Postmenopausal
A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Indian postmenopausal women with osteoporosis.
- Trial name
- NCT01495000
- Testing
- denosumab
- Where
- 11 sites in India
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Post-Menopausal Osteoporosis
A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP)…
- Trial name
- NCT03432533
- Testing
- romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
- Where
- 46 sites in United States, Poland and 1 more
- Volunteers
- 283 people
- Sponsor
- Amgen
Osteoporosis, Postmenopausal
A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women
The purpose of this study is to evaluate the tolerability of two different formulations of blosozumab in women who have reached menopause. This study will last approximately 12 weeks for each participant, not including screening.
- Trial name
- NCT02337387
- Testing
- Blosozumab
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Osteoporosis, Postmenopausal
A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women
The purpose of this study is to compare the effectiveness and tolerability of two medications, calcitonin nasal spray and a tablet containing calcitonin, in postmenopausal women with osteoporosis.
- Trial name
- ORACAL (NCT00959764)
- Testing
- Oral Calcitonin Tablets, Intranasal Calcitonin
- Where
- 20 sites in United States, Bulgaria and 4 more
- Volunteers
- 565 people
- Sponsor
- Tarsa Therapeutics, Inc.
Menopause, Osteoporosis
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
The purpose of this research study is to evaluate the safety and effectiveness of this investigational drug for the treatment of menopausal symptoms while protecting the endometrium (uterine lining) and preventing postmenopausal…
- Trial name
- NCT00808132
- Testing
- bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg
- Where
- 178 sites in United States, Argentina and 10 more
- Volunteers
- 1,886 people
- Sponsor
- Pfizer
Post Menopausal Osteoporosis
DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
This study will assess the efficacy and safety of intravenous administration of Bonviva regimens in women with post-menopausal osteoporosis, compared to oral daily administration.
- Trial name
- NCT00048074
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 64 sites in United States, Australia and 14 more
- Volunteers
- 1,395 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms, Osteoporosis
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
This protocol is designed to compare the effect on bone of Zoledronic Acid 4 mg every 6 months when given upfront versus delayed start (based on a post-baseline BMD T- Score below -2.0 SD at either the lumbar spine or total hip…
- Trial name
- NCT00050011
- Testing
- Zoledronic Acid, Letrozole
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals
Low Bone Mineral Density
Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density
To determine the effect of denosumab treatment compared with placebo over 12 months on bone mineral density (BMD) of the lumbar spine in postmenopausal women with low BMD.
- Trial name
- NCT00043186
- Testing
- Denosumab, Alendronate
- Volunteers
- 412 people
- Sponsor
- Amgen
Postmenopausal Women With Osteoporosis
Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis
This is a randomized, double-blind, multicenter, parallel-arm, Phase 3 study to compare the efficacy, PK (Pharmacokinetic), PD (Pharmacodynamic), safety, and immunogenicity of Bmab 1000 and Prolia® in postmenopausal women with…
- Trial name
- DEVOTE (NCT05345691)
- Testing
- Bmab 1000, Prolia®
- Where
- United Kingdom
- Volunteers
- 479 people
- Sponsor
- Biocon Biologics UK Ltd
Osteopenia, Osteoporosis
Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
The purpose of this study is to evaluate the changes in bone structure as determined by magnetic resonance imaging measurements among early postmenopausal women after 24 months of treatment with alendronate, 70 mg once a week as…
- Trial name
- NCT00504166
- Testing
- alendronate sodium
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of California, San Francisco
Osteoporosis
Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis
A Multi-center study to determine effects of various doses of Macroflux Parathryroid Hormone (PTH) in women with osteoporosis
- Trial name
- NCT00489918
- Testing
- teriparatide
- Volunteers
- 165 people
- Sponsor
- Zosano Pharma Corporation
Osteoporosis, Osteopenia
Texture Analysis for Postmenopausal Osteoporosis
The purpose of this study is to determine if a new test for osteoporosis can be useful in monitoring treatment. We are studying a new method for examining the quality of bone by an experimental method of computerized analysis of…
- Trial name
- NCT00145977
- Testing
- Alendronate, Calcium Citrate, Vitamin D
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Chicago
Low Bone Mass, Low Bone Mineral Density
A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
To characterize the effects of discontinuation of denosumab therapy on variables of bone histology in postmenopausal women with low bone mass or osteoporosis.
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Osteoporosis, Postmenopausal Osteoporosis
- Trial name
- NCT00887965
- Testing
- Previous denosumab
- Volunteers
- 15 people
- Sponsor
- Amgen
Osteoporosis
Study Evaluating Changes In Mammographic Breast Density
The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg…
- Trial name
- NCT00774267
- Testing
- BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg
- Where
- 26 sites in United States, Brazil and 2 more
- Volunteers
- 507 people
- Sponsor
- Pfizer
Osteoporosis
A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
The purpose of the study is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on the percent changes in bone mineral density (BMD) at the lumbar spine, at the total hip and femoral neck in…
- Trial name
- NCT05067335
- Testing
- Romosozumab
- Where
- 30 sites in China
- Volunteers
- 327 people
- Sponsor
- UCB Biopharma SRL
Osteoporosis, Post-menopausal
Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women
The purpose of this study is to investigate how teriparatide or zoledronic acid affects the bone of postmenopausal osteoporotic women after 6 months of treatment as determined by a bone biopsy sample taken from the iliac crest…
- Trial name
- NCT00927186
- Testing
- Teriparatide, Zoledronic Acid
- Where
- 12 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Eli Lilly and Company